文献速递MDS 与骨髓增殖性肿瘤白血病

既存自身免疫性疾病对骨髓增生异常综合征结局的影响:一项人群分析

Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis.
PubMed 文献 · Blood Adv · 2023-01-01

利用监测、流行病学和最终结果(SEER)医疗保险数据库,对2007至2017年确诊的15277例骨髓增生异常综合征(MDS)患者进行分析,其中2442例(16%)存在既存自身免疫性疾病。自身免疫性疾病与死亡风险降低11%相关(HR 0.89,95%CI 0.85-0.94,P<.001);在低危MDS组织学亚型中,自身免疫性疾病与白血病转化风险增加1.9倍相关(HR 1.87,95%CI 1.17-2.99,P=.008),其他组未见显著影响。

要点

  • MDS患者中既存自身免疫性疾病者更年轻、以女性为主、输血负担更高,MDS组织学分布无差异。
  • 自身免疫性疾病与MDS患者死亡风险降低11%相关(HR 0.89,95%CI 0.85-0.94,P<.001)。
  • 低危MDS组织学亚型中自身免疫性疾病与白血病风险增加1.9倍相关(HR 1.87,95%CI 1.17-2.99,P=.008)。

核心结论

  • 自身免疫性疾病影响MDS患者生存,与死亡率降低相关。
  • 在低危组织学亚型中,尽管白血病进展风险更高,生存获益仍然明显。
  • 作者认为这可能代表炎症驱动的造血,同时倾向于较低侵袭性表型和克隆扩增,需进一步研究。

研究设计与样本

  • 利用监测、流行病学和最终结果(SEER)医疗保险数据库进行的人群分析。
  • 病例 ascertained 于2007年至2017年。
  • 使用索赔算法识别自身免疫性疾病、人口学特征、合并症评分、MDS组织学、输血负担、去甲基化药物治疗和造血干细胞移植。
  • 采用Cox回归模型估计对生存的影响,竞争风险回归模型定义对白血病转化的影响。
  • 分析了15277例MDS患者,其中2442例(16%)存在既存自身免疫性疾病。

主要发现

  • 既存自身免疫性疾病患者的流行病学特征独特:更年轻、以女性为主、输血负担更高,MDS组织学分布无差异。
  • 自身免疫性疾病与死亡风险降低11%相关(HR 0.89,95%CI 0.85-0.94,P<.001)。
  • 对白血病转化风险的影响因MDS组织学而异:低危MDS组织学中,自身免疫性疾病与白血病风险增加1.9倍相关(HR 1.87,95%CI 1.17-2.99,P=.008),其他组未见显著影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preexisting autoimmune disease affects between 10% and 30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in patients with MDS with and without autoimmune disease show discordant results. Using the Surveillance, Epidemiology, and End Results Medicare database, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 and 2017 and claim algorithms used to identify autoimmune disease, demographic characteristics, comorbidity scores, MDS histology, transfusion burden, treatment with hypomethylating agents, and hematopoietic stem cell transplantation. Cox regression models estimated the impact on survival, and competing-risk regression models defined the effect on leukemic transformation. We analyzed 15 277 patients with MDS, including 2442 (16%) with preexisting autoimmune disease. The epidemiologic profile was distinctive in cases with preexisting autoimmunity, who were younger, were predominantly female, and had higher transfusion burden without difference in MDS histologic distribution. Autoimmune disease was associated with 11% decreased risk of death (hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.85-0.94; P < .001). The effect on risk of leukemic transformation differed based on MDS histology. In low-risk MDS histologies, autoimmunity was associated with a 1.9-fold increased risk of leukemia (HR, 1.87; 95% CI, 1.17-2.99; P = .008), whereas no significant effect was seen in other groups. These results suggest that autoimmune disease affects survival in MDS and is associated with decreased mortality. The survival effect was evident in low-risk histologies despite higher risk of progression to leukemia. This could represent inflammation-driven hematopoiesis, simultaneously favoring less aggressive phenotypes and clonal expansion, which warrants further investigation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Adrianzen-Herrera D, Sparks AD, Singh R, et al. Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis. Blood Adv. 2023. PMID: 37729616. doi:10.1182/bloodadvances.2023011050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。